SNS-032, a CDK9 selective inhibitor, has entered clinical trials for the treatment of AML, CLL, and multiple myeloma (Tong et al., 2010; Walsby et al., 2011). This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.